Should I Buy Alcoa Stock?
Alcoa (AA) finds itself in an interesting position in early…
Buy
51
PHR Quote, Financials, Valuation and Earnings
Last price:
$26.11
Seasonality move
:
6.34%
Day range:
$24.94 - $26.07
52-week range:
$17.07 - $30.53
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.49x
P/B ratio:
5.65x
Volume:
420.3K
Avg. volume:
539.4K
1-year change:
10.31%
Market cap:
$1.5B
Revenue:
$419.8M
EPS (TTM):
-$1.02
Analysts' Opinion
-
Consensus RatingPhreesia has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $32.31, Phreesia has an estimated upside of 26.9% from its current price of $25.46.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $29.00 representing -13.9% downside risk from its current price of $25.46.
Fair Value
-
According to the consensus of 9 analysts, Phreesia has 26.9% upside to fair value with a price target of $32.31 per share.
PHR vs. S&P 500
-
Over the past 5 trading days, Phreesia has underperformed the S&P 500 by -8.43% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Phreesia does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Phreesia has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Phreesia reported revenues of $109.7M.
Earnings Growth
-
Phreesia has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Phreesia reported earnings per share of -$0.11.
Enterprise value:
1.4B
EV / Invested capital:
5.30x
Price / LTM sales:
3.49x
EV / EBIT:
--
EV / Revenue:
3.37x
PEG ratio (5yr expected):
--
EV / Free cash flow:
170.53x
Price / Operating cash flow:
176.81x
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$284.9M
Return On Assets:
-15.66%
Net Income Margin (TTM):
-13.94%
Return On Equity:
-22.95%
Return On Invested Capital:
-22.86%
Operating Margin:
-6.94%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-31 | 2024-01-31 | 2025-01-31 | 2024-01-31 | 2025-01-31 | |
| Income Statement | ||||||
| Revenue | $280.9M | $356.3M | $419.8M | $95M | $109.7M | |
| Gross Profit | $171.6M | $232.3M | $284.9M | $63.2M | $76.1M | |
| Operating Income | -$176.6M | -$136.5M | -$58.1M | -$29.6M | -$7.6M | |
| EBITDA | -$148.9M | -$104M | -$25.6M | -$21.6M | $2M | |
| Diluted EPS | -$3.36 | -$2.52 | -$1.02 | -$0.56 | -$0.11 | |
| Period Ending | 2021-01-31 | 2022-01-31 | 2023-01-31 | 2024-01-31 | 2025-01-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $272.3M | $386.3M | $262.4M | $195.7M | $203.3M | |
| Total Assets | $326.7M | $494.5M | $370.1M | $370.3M | $388.4M | |
| Current Liabilities | $55M | $68.4M | $79M | $110.1M | $114M | |
| Total Liabilities | $63.4M | $77.2M | $82.2M | $118.9M | $123.6M | |
| Total Equity | $263.3M | $417.3M | $287.8M | $251.4M | $264.8M | |
| Total Debt | $11.3M | $13.2M | $246K | $3.1M | $1.9M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-01-31 | 2024-01-31 | 2025-01-31 | 2024-01-31 | 2025-01-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$90.1M | -$32.4M | $32.4M | -$3.1M | $16.3M | |
| Cash From Investing | -$26.2M | -$39.7M | -$24.1M | -$8.2M | -$7.1M | |
| Cash From Financing | -$20.8M | -$17.1M | -$11.5M | -$4.6M | -$6.6M | |
| Free Cash Flow | -$116.3M | -$57.5M | $8.3M | -$10.9M | $9.2M | |
PHR
Sector
Market Cap
$1.5B
$35.9M
Price % of 52-Week High
83.39%
42.55%
Dividend Yield
0%
0%
Shareholder Yield
-0.02%
-1.03%
1-Year Price Total Return
10.31%
-44.4%
Beta (5-Year)
0.823
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$26.86
200-day SMA
Buy
Level
$23.69
Bollinger Bands (100)
Buy
Level
21.84 - 28.36
Chaikin Money Flow
Buy
Level
24.1M
20-day SMA
Sell
Level
$26.14
Relative Strength Index (RSI14)
Sell
Level
43.61
ADX Line
Sell
Level
18.57
Williams %R
Neutral
Level
-67.9193
50-day SMA
Sell
Level
$27.35
MACD (12, 26)
Sell
Level
-0.16
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
27.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.1266)
Buy
CA Score
(Annual)
Level (0.1626)
Buy
Beneish M-Score
(Annual)
Level (-3.4199)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (1.1449)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Phreesia Inc is a provider of comprehensive software solutions that improve the operational and financial performance of healthcare organizations by activating patients in their care to optimize patient health outcomes. Through its SaaS-based technology platform, it offers healthcare services clients a robust suite of integrated solutions that manage patient access, registration, payments, and clinical support. The Phreesia Platform encompasses a comprehensive range of technologies and services, including, initial patient contact, registration, automated answering services, appointment scheduling, payments, and post-appointment patient surveys.
Stock Forecast FAQ
In the current month, PHR has received 9 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PHR average analyst price target in the past 3 months is $32.31.
-
Where Will Phreesia Stock Be In 1 Year?
According to analysts, the consensus estimate is that Phreesia share price will rise to $32.31 per share over the next 12 months.
-
What Do Analysts Say About Phreesia?
Analysts are divided on their view about Phreesia share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Phreesia is a Sell and believe this share price will drop from its current level to $29.00.
-
What Is Phreesia's Price Target?
The price target for Phreesia over the next 1-year time period is forecast to be $32.31 according to 9 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PHR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Phreesia is a Buy. 9 of 9 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PHR?
You can purchase shares of Phreesia via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Phreesia shares.
-
What Is The Phreesia Share Price Today?
Phreesia was last trading at $26.11 per share. This represents the most recent stock quote for Phreesia. Yesterday, Phreesia closed at $25.46 per share.
-
How To Buy Phreesia Stock Online?
In order to purchase Phreesia stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will Nu Holdings Stock Be in 2030?
Despite fast growth, high profitability and an extraordinary runway ahead,…
Is it Too Late to Buy United Airlines Stock?
United Airlines (NASDAQ:UAL) has thoroughly outpaced the broader stock market…
Stock Ideas
Buy
56
Is AAPL Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 37x
Sell
46
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
78
GATE alert for Apr 2
Marblegate Acquisition [GATE] is up 86.64% over the past day.
Buy
52
NUTX alert for Apr 2
Nutex Health [NUTX] is up 5.41% over the past day.
Buy
75
CORT alert for Apr 2
Corcept Therapeutics [CORT] is down 8.84% over the past day.
